Tempus AI's stock saw a significant rise after important regulatory news.
Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM) increased by 9.03% yesterday, closing at CA$83.55. This jump was mainly due to the company receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative AI tool aimed at early detection of mitral regurgitation.
Advertisement
Tempus AI, Inc. Class A Common Stock
TEM.US
TEM.US
Tempus AI, Inc. Class A Common Stock
WealthAwesomeMarket cap
$15.08B
52W high
$104.32
52W low
$40.77
1W change
-1.80%
Beta
3.54
Analyst Price Targets
Based on analyst covering TEM · as of Oct 5, 2026
Wall Street analysts forecast TEM stock price to fall 16.2% over the next 12 months.
Consensus
BearishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$70.06
-16.2% Upside
Previously C$68.56 on Sep 23, 2026
Current Price
C$83.55
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TEM's historical volatility
30-Day Vol
83.3%
Annualized
90-Day Vol
86.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$99.88
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$88.67 | C$66.53 – C$118.18 |
| 60 trading days | C$94.11 | C$62.69 – C$141.28 |
| 90 trading days | C$99.88 | C$60.73 – C$164.28 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are feeling more optimistic about Tempus AI's growth potential in healthcare, especially as the company expands its AI-driven product offerings.
9.03%
Tempus AI's stock price has risen a notable 29.29% over the last 30 days, showing strong short-term momentum.
Bull case
The FDA clearance for Tempus ECG-MR puts the company in a great position to take advantage of the growing AI-ECG market, which is expected to grow significantly. Additionally, Tempus AI's revenue growth and raised guidance indicate strong operational momentum.
Bear case
Even with the positive news, analysts see Tempus AI's stock as potentially overvalued at its current price. If growth expectations don’t pan out as hoped, there could be a correction.
FDA Clearance Boosts Investor Confidence
Advertisement
The recent FDA clearance for Tempus ECG-MR has been a key moment for Tempus AI, boosting investor confidence. This AI tool analyzes standard ECGs for signs of mitral regurgitation, a common heart issue. With the healthcare AI market set for significant growth, this approval positions Tempus to capture a larger market share.
Strong Revenue Growth and Future Guidance
Tempus AI reported an impressive 22% year-over-year revenue growth in Q2, with oncology testing volumes up 31%. The company has also raised its revenue guidance for 2026 to about $1.6 billion, showing that its growth strategy is starting to pay off. This positive trend is drawing interest from investors looking for opportunities in healthcare technology.
Market Valuation Concerns Persist
Despite the recent surge, analysts warn that Tempus AI's stock may be overvalued at $83.55, compared to a fair value estimate of around $75.68. Investors should weigh the risks associated with high expectations for the company’s future growth and product integration.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
